Risk analysis for outpatient experimental infection as a pathway for affordable RSV vaccine development
Issued Date
2025-12-01
Resource Type
eISSN
20590105
Scopus ID
2-s2.0-105002709336
Journal Title
npj Vaccines
Volume
10
Issue
1
Rights Holder(s)
SCOPUS
Bibliographic Citation
npj Vaccines Vol.10 No.1 (2025)
Suggested Citation
Siegal E.Z., Schoevers J.M.H., Terstappen J., Delemarre E.M., Johnston S.L., van Beek L.F., Bogaert D., Chiu C., Diavatopoulos D.A., Ferreira D.M., Gordon S.B., Hayden F.G., de Jonge M.I., McCall M.B.B., McShane H.I., Minassian A.M., Openshaw P.J.M., Pollard A.J., Sattabongkot J., Read R.C., Troelstra A., Viveen M.C., Wilder-Smith A., van Wijk M., Bont L.J., Mazur N.I. Risk analysis for outpatient experimental infection as a pathway for affordable RSV vaccine development. npj Vaccines Vol.10 No.1 (2025). doi:10.1038/s41541-025-01125-w Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/109743
Title
Risk analysis for outpatient experimental infection as a pathway for affordable RSV vaccine development
Author(s)
Siegal E.Z.
Schoevers J.M.H.
Terstappen J.
Delemarre E.M.
Johnston S.L.
van Beek L.F.
Bogaert D.
Chiu C.
Diavatopoulos D.A.
Ferreira D.M.
Gordon S.B.
Hayden F.G.
de Jonge M.I.
McCall M.B.B.
McShane H.I.
Minassian A.M.
Openshaw P.J.M.
Pollard A.J.
Sattabongkot J.
Read R.C.
Troelstra A.
Viveen M.C.
Wilder-Smith A.
van Wijk M.
Bont L.J.
Mazur N.I.
Schoevers J.M.H.
Terstappen J.
Delemarre E.M.
Johnston S.L.
van Beek L.F.
Bogaert D.
Chiu C.
Diavatopoulos D.A.
Ferreira D.M.
Gordon S.B.
Hayden F.G.
de Jonge M.I.
McCall M.B.B.
McShane H.I.
Minassian A.M.
Openshaw P.J.M.
Pollard A.J.
Sattabongkot J.
Read R.C.
Troelstra A.
Viveen M.C.
Wilder-Smith A.
van Wijk M.
Bont L.J.
Mazur N.I.
Author's Affiliation
Faculty of Tropical Medicine, Mahidol University
Wilhelmina Kinderziekenhuis
University Medical Center Utrecht
University of Virginia School of Medicine
St. Antonius Ziekenhuis
University of Southampton, Faculty of Medicine
Liverpool School of Tropical Medicine
MRC Centre for Inflammation Research
Universität Heidelberg
National Heart and Lung Institute
University of Oxford Medical Sciences Division
Radboud University Medical Center
Virtus Respiratory Research Ltd
Respiratory Syncytial Virus Network (ReSViNET)
Wilhelmina Kinderziekenhuis
University Medical Center Utrecht
University of Virginia School of Medicine
St. Antonius Ziekenhuis
University of Southampton, Faculty of Medicine
Liverpool School of Tropical Medicine
MRC Centre for Inflammation Research
Universität Heidelberg
National Heart and Lung Institute
University of Oxford Medical Sciences Division
Radboud University Medical Center
Virtus Respiratory Research Ltd
Respiratory Syncytial Virus Network (ReSViNET)
Corresponding Author(s)
Other Contributor(s)
Abstract
Controlled human infection models (CHIMs) are an important tool for accelerating clinical development of vaccines. CHIM costs are driven by quarantine facilities but may be reduced by performing CHIM in the outpatient setting. Furthermore, outpatient CHIMs offer benefits beyond costs, such as a participant-friendly approach and increased real-world aspect. We analyze safety, logistic and ethical risks of respiratory syncytial virus (RSV) CHIM in the outpatient setting. A review of the literature identified outpatient CHIMs involving respiratory pathogens. RSV transmission risk was assessed using data from our inpatient and outpatient RSV CHIMs (EudraCT 020-004137-21). Fifty-nine outpatient CHIMs using RSV, Streptococcus pneumoniae, rhinovirus, and an ongoing Bordetella Pertussis outpatient CHIM were included. One transmission event was recorded. In an inpatient RSV CHIM, standard droplet and isolation measures were sufficient to limit RSV transmission and no symptomatic third-party transmission was measured in the first outpatient RSV CHIM. Logistic and ethical advantages support outpatient CHIM adoption. We propose a framework for outpatient RSV CHIM with risk mitigation strategies to enhance affordable vaccine development.